Cancer patients report more memory lapses, study finds
NCT ID NCT03975959
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looked at memory complaints in 426 people, including those with brain tumors, breast cancer, and healthy volunteers. Participants filled out questionnaires about their memory, mood, and fatigue. The goal was to understand how cancer and its treatments might affect everyday memory, especially the ability to remember future tasks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help identify new targets for psychological support to improve memory complaints in cancer patients.
- What could go wrong
- This is an observational study, not a treatment trial. It only measures subjective complaints, so it may not lead to direct improvements.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
426 people
The number who actually took part.
- Started
-
May 2019
- Finished
-
Oct 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: All the participants must fulfill all the following criteria to be eligible for study entry: * Be aged of 18 to 80 years old * Have a ECOG Performance Status ≤ 2 or a Karnofsky index ≥ 50 % * Have a satisfactory level of French * Have signed the informed consent Also, for the DLGG group, the patients must: * Have a histologically-proven diagnosis of DLGG (i.e., WHO grade II glioma) * Receive or have received a first oncological treatment after surgery (chemotherapy, radiation therapy…) Also, for the GB group, the patients must: \- Have a histologically-proven diagnosis of GB (i.e., WHO grade IV glioma). Also, for the breast cancer group, the patients must: \- Have a histologically-proven diagnosis of breast cancer diagnosed \< 2 years. Exclusion Criteria: Participants presenting with any of the following exclusion criteria will not be included in the study: * Patients with brain metastases * Patients under tutorship or curatorship or protective measures * Patients suffering from sensorial or motor deficits avoiding the tests administration * Patients with a reported history of psychiatric disease (e.g., mental retardation, psychotic disorders, learning disabilities, attention-deficit/hyperactivity disorder, and bipolar disorder) * Have reported a substance dependence within the past six months (e.g., cocaine or methamphetamine dependence) * Pregnant women * Legal incapacity or physical, psychological social or geographical status interfering with the patient's ability to sign the informed consent or to terminate the study Also, for the DLGG group, the patients must not: * Have an anaplastic glioma (i.e., WHO grade III glioma) * Have a DLGG with radiological or histological signs of anaplastic transformation * Have a history of HIV * Have a history of other cancer Also, for the GB group, the patients must not: * Patients treated with ≥2 lines of systemic cancer treatment (e.g., patient after the first GB recurrence) * Have a history of HIV * Have a history of other cancer Also, for the breast cancer group, the patients must not: * Have a metastatic disease * Have a neoadjuvant therapy * Have a documented neurological, or substance use disorders. * Have a history of HIV * Have a history of other cancer * Have reported a history of neurological diagnoses (e.g., seizure disorders, closed head injuries with loss of consciousness greater than 15 min). Also for the control group, the participants must not: * Have a documented neurological, or substance use disorders * Have a history of cancer * Have a history of HIV
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU D'amiens
Amiens, Nord, 80080, France
-
CHU Lyon
Saint-Genis-Laval, 69230, France
-
Hopital saint Louis
Paris, 75010, France
-
Hôpital d'Instruction des Armées
Clamart, 92190, France
-
Icm Val D'Aurelle
Montpellier, Herault, 34298, France
-
UFR de Psychologie Université de Lille
Villeneuve-d'Ascq, NORD, 59653, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- New PET tracer aims to light up hidden cancer targets
- Can a protein powder with creatine and fiber boost everyday Well-Being?
- Experimental therapy aims to turn brain tumors against themselves
- Gut bacteria supplement tested against chemo hair loss